Villanueva, Rita <br/><br/>
Heparin (GAG-hed) inhibits LCR activity of human papillomavirus type 18 by decreasing AP1 binding.  [electronic resource] 

 -  BMC cancer  Aug 2006 
 - 218 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-6-218  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antiviral Agents--pharmacology<br/>Apoptosis--drug effects<br/>Cell Cycle--drug effects<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>DNA-Binding Proteins--metabolism<br/>Down-Regulation--drug effects<br/>Female<br/>HeLa Cells<br/>Heparin--pharmacology<br/>Human papillomavirus 18--drug effects<br/>Humans<br/>Locus Control Region--drug effects<br/>Mice<br/>Mice, Nude<br/>Mice, Transgenic<br/>Models, Biological<br/>Protein Binding--drug effects<br/>Regulatory Sequences, Nucleic Acid<br/>Transcription Factor AP-1--metabolism<br/>Transcription, Genetic--drug effects<br/>Uterine Cervical Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays